NIKITA (pitavastatin sodium) by Lupin Ltd. is 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase, the enzyme that catalyzes the conversion of hmg-coa to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. First approved in 2017.
Drug data last refreshed 23h ago · AI intelligence enriched 1mo ago
NIKITA is a pitavastatin sodium oral tablet, a statin that inhibits HMG-CoA reductase to lower cholesterol synthesis in the liver. It reduces LDL and VLDL levels by accelerating LDL-receptor expression and uptake from blood, making it a standard-of-care therapy for dyslipidemia and cardiovascular risk reduction.
Product is at peak commercial maturity with moderate competitive pressure (30 index), suggesting stable but potentially defensive market positioning requiring efficiency-focused marketing.
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on NIKITA offers stability in a peak-stage product with established patient population and clear medical need, but limited upside growth and high generic competition pressure. Career trajectory is suited for professionals seeking to master defensive marketing, payer negotiation, and patient retention strategies in a commoditizing therapeutic class.
Worked on NIKITA at Lupin Ltd.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.